

IA2030 Strategic Priority 7: Research & Innovation. Overview and goals

Kwaku Poku Asante, MD, MPH, PhD, FWACPS

Director, Kintampo Health Research Centre, Research and Development Division, Ghana Health Service

Global Vaccine and Immunisation Research Forum

28th March, 2023


South Korea

Immunization Agenda 2030

A global strategy to **leave no one behind**

7 strategic priorities (SPs)

1. Immunization programmes for primary health care / universal health coverage
2. Commitment & demand
3. Coverage & equity
4. Life-course & integration
5. Outbreaks & emergencies
6. Supply & sustainability
7. **Research & innovation**




Goal and focus of SP7

- Fostering an **enabling environment** and ensuring that research and innovations that **increase the reach and impact of immunization programs** are rapidly and equitably made available to all countries and communities
- Supporting **greater capacity** for research and innovation by improving the research and innovation ecosystem and striving for both **breakthrough discoveries** that change the landscape (e.g., mRNA-based vaccines), while also advancing **incremental innovations** for continual improvements designed to leave no one behind (e.g., combination vaccines)
- Ensuring **equitable access** of innovative products and programs **to all countries and communities**

Partners and programs to leverage

- GVIRF (Global Vaccine and Immunization Research Forum)
- Gavi 5.0, VIPS (Vaccine Innovation Prioritisation Strategy) and VIS (Gavi Vaccine Investment Strategy renewals)
- CEPI 2.0
- WHO CAPACITI (Country-led Assessment for Prioritization in Immunization Decision-support Framework)
- COVAX and its successor, if any, post-pandemic
- WHO AMRVAF (Anti-Microbial Resistance Value Attribution Framework)
- WHO R&D Blueprint

SP7 2022 – 2023 workplan



Key Focus Areas and Deliverables 2022-2023

- Support LMICs in expanding, strengthening, and/or establishing local and regional capacities for immunization research and innovation
 - **Obj 7.1 indicator:** No. of countries with national agenda for research on immunization;
- Develop a mechanism to align country, regional, and global level stakeholders on priority diseases for which new vaccines are needed
 - **Obj 7.2 indicator:** (potential) process review at SAGE in Oct 2022; global “short list” of pipeline pathogen targets will be developed by WHO and first iteration endorsed by SAGE in April 2023
- Establish 2025 and 2030 IA2030 SP7 Working Group objectives to sustain progress, based on country-led R&D priorities.

*WHO’s Strategic Advisory Group of Experts on Immunization (SAGE):

** WHO’s Product Development for Vaccines Advisory Committee (PDVAC): <https://www.who.int/groups/product-development-for-vaccines-advisory-committee>

Highlights of SP7 reports

- SP 7.1 Capacity for Innovation
 - Indicator
 - Proportion of countries with an immunization research agenda
 - Progress
 - Relatively few countries found to have a national agenda for research on immunization
 - Considerations to improve indicator
 - Encourage countries to develop stand-alone research agendas on immunization or integrate research priorities into broader health systems research strategies.
 - Research agendas could also be developed at the regional level and provide countries with examples as guides to defining their research priorities for immunization within their local context.

STRATEGIC FRAMEWORK FOR RESEARCH ON IMMUNIZATION IN THE WHO AFRICAN REGION

IMMUNIZATION AND VACCINE DEVELOPMENT

WORLD HEALTH ORGANIZATION
REGIONAL OFFICE FOR AFRICA
BRAZZAVILLE•2018


Highlights of SP7 reports

- SP 7.2 New Vaccine development
 - Indicator
 - Progress towards global research and development targets
 - Progress
 - Ongoing collaboration between SP7 WG and PDVAC to develop priority pathogen list
 - Development of a mechanism and methodology to identify priority pathogens for new vaccine development (PAPRIKA) reviewed by PDVAC
 - Highlighted the need to define use(s) of the priority list(s) – country vaccine production, multilateral, biotechs
 - Regional stakeholder engagements planned to identify regional and global priority list(s)

Highlights of SP7 report

- SP 7.3 Evaluate promising innovations and scale up innovations
 - Indicator
 - No indicator yet, under development
 - Progress
 - Observed that there are no well-defined indicator for implementation /operational research exists
 - Engagement process for evaluating implementation /operational research agendas do not currently exist at national, regional, and global levels
 - SP7 WG discussing how to close the gap → A key SP7 activity for 2023 - 2024

Success of SP7 approach relies on the framework for regional engagement **Potential model for consideration**



RITAG WGs composed of at least 2 RITAG members, plus other regional experts, including NITAG members;

2 RITAG WG members serve as regional representatives on IA2030 SP7 WG

Recommendations to SAGE (e.g., priority pathogens via PDVAC*)

* WHO's Product development for Vaccines Advisory Committee

Summary

- SP7 seeks to contribute to innovative research to accelerate vaccine discovery to delivery
- Leverage
 - Renewed interest in immunization
 - Lessons learnt from unprecedented Covid 19 vaccine discovery to delivery ==> **13 billion** doses delivered to a wider age group. !!
 - How can the global vaccine community apply these lessons to the pathogen priority list?
- Rapid deployment of new and existing vaccines
 - Lessons learnt from malaria vaccines introduction
 - From 2019 – 2022, 50 million children in 20 countries missed doses of existing vaccines ==> innovative research evidence to reach them

Membership

Up to **18** members, with:

- up to **12 independent** members (target 2 members / WHO region)
- up to **6 ex officio** members from core IA2030 partners
 - WHO
 - Gavi
 - CEPI
 - UNICEF
 - NIH
 - Wellcome Trust

Members	Name Co-leads in bold	Status
AFRO	Kwaku Poku Asante (AFRO)	Confirmed
	Helen Rees	Confirmed
EMRO	Ghassan Dbaibo	Confirmed
	Ahmed Deemas Al Suwaidi (NITAG-UAE)	Confirmed
EURO		<i>Contacted</i>
		<i>Contacted</i>
PAHO/AMRO	David C. Kaslow (PDVAC)	Past colead
	Dr Cristiana Toscano (RITAG)	Confirmed
	John Peter Figueroa (RITAG)	Confirmed
SEARO	<i>Gagandeep Kang</i> (SEAR ITAG)	Contacted
	Mimi Lhamu Mynak (SEAR ITAG Bhutan)	Confirmed
WPRO	<i>Chris Morgan</i>	Contacted
		Contacted
Ex officio IA2030 core partners	Name	Contact / confirmation status
WHO PDU EPI	Birgitte Giersing Anna-Lea Kahn	Confirmed
UNICEF	Robert Scherpbier Jean-Pierre Amori	Confirmed
US CDC/NIH	Jim Alexander B. Lee Hall	Confirmed Contacted
Wellcome Trust	Charlie Weller	Confirmed
GAVI	Marion Menozzi-Arnaud	Confirmed
CEPI	Adam Hacker	Confirmed

Thank you!




Photo credit: Shifa Foundation

IMMUNIZATION AGENDA 2030

A global strategy to leave no one behind

